Recipharm will be implementing squeeze-out of Consort Medical shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. THIS PUBLICATION IS NEITHER AN OFFER TO BUY OR SELL NOR AN INVITATION TO TENDER OR OFFER TO BUY OR SELL SHARES. As at 12.00 p.m. (London time) on 17 February 2020, Recipharm announced that it controlled a total of 45,594,690 Consort Medical plc (“Consort”) shares, representing approximately 91.3 per cent. of the issued share capital of Consort. Recipharm will soon be implementing the procedure to